Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy Subjects

Phase 1

Active, not recruiting

• Conditions: Healthy
• Interventions: Drug: GB001 recombinant peptide spray; Drug: Placebo

• Registration Number: NCT05125211
• Lead Sponsor: Zhejiang Echon Biopharm Limited

Brief Summary

This trial is conducted in China. The aim of this clinical trial is to assess the safety , tolerability and pharmacokinetics profiles of GB001 by single ascending dose and multiple ascending doses in healthy subjects after topical buccal delivery.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-10-24
• Study First Submitted QC: 2021-11-07
• Study First Posted: 2021-11-18
• Study Start: 2022-08-08
• Primary Completion: 2022-11-18
• Status Verified: 2024-04
• Last Update Submitted: 2025-04-08
• Last Update Posted: 2025-04-09
• Study Completion: 2026-05-29

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 91

Inclusion Criteria

1. Healthy males or females aged 18 to 45 years, with a body mass index(BMI) 19-26kg/m2 and body weight no less than 45 kg (female) or 50 kg (male).
2. The results in the screening examinations (including general physical examination, vital signs, laboratory examinations, electrocardiogram, chest radiograph, etc.) are in the normal range, or are abnormal without clinical significance assessed by the investigator.
3. Subjects and their sexual partners agree to take effective contraceptive measures during the study period and at least 3 days after the end of the study.
4. Understanding and willing to comply strictly with the clinical trial protocol, complete all test procedures required in this trial, understand and sign informed consent form.

Exclusion Criteria

1. Those allergic to GB001 peptide or any other drugs, or suffered from allergic disease or allergic constitution.
2. Any obvious clinical symptoms or abnormal test results with clinical significance suggested organ or system illness, unsuitable for inclusion in this trial in the investigator's judgement.
3. Subjects has obvious oral lesions or diseases, such as erosion of oral mucosa, ulcer or obvious periodontitis.
4. The weekly alcohol intake in 90 days before screening is more than 21 units (male) and more than 14 units (female) , or the subject is unwilling to stop drinking whenever required for the trial procedure.
5. Subject who smoke more than 10 cigarettes per day or is unwilling to stop smoking whenever required for the trial procedure.
6. Subject with a history of drug abuse, or those with positive urine screening test for drug abuse.
7. Subject who use of any other drugs within 30 days prior to screening, including prescription drugs, non-prescription drugs, biologicals, vitamins, minerals and nutritional supplements.
8. Blood loss or blood donation more than 400 mL within 90 days prior to screening.
9. Received major surgery within 90 days prior to screening, or participated in any other drug/device clinical trial.
10. Pregnant or lactating women; or female subject of childbearing age have a positive serum pregnancy test result during the screening.
11. Subject with dizzy needle or difficulty in venous blood collection.
12. Subject unsuitable for the trial in the judgement of the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Single dose-escalation of GB001 recombinant peptide spray	GB001 recombinant peptide spray	Each subject will receive one single administration of GB001 recombinant peptide. The dosage of each group is 0.054mg, 0.108mg, 0.216mg, 0.432mg and 0.864mg, respectively.
Single dose-escalation of GB001 recombinant peptide spray	Placebo	Each subject will receive one single administration of GB001 recombinant peptide. The dosage of each group is 0.054mg, 0.108mg, 0.216mg, 0.432mg and 0.864mg, respectively.
Multiple Ascending Dose of GB001 recombinant peptide spray	Placebo	Each subject will be dosed with oral spray of GB001 recombinant peptide ten times per day for four days. GB001 recombinant peptide will be administrated, and the dosage of each group is 0.108mg, 0.216mg and 0.432mg, respectively.
Oral retention time test for a single dose	GB001 recombinant peptide spray	Each subject will receive one single administration of GB001 recombinant peptide. The dosage of the group is 0.108mg.
Multiple Ascending Dose of GB001 recombinant peptide spray	GB001 recombinant peptide spray	Each subject will be dosed with oral spray of GB001 recombinant peptide ten times per day for four days. GB001 recombinant peptide will be administrated, and the dosage of each group is 0.108mg, 0.216mg and 0.432mg, respectively.

Primary Outcome Measures

Name	Time	Method
Incidence of adverse events	Through the study completion, an average of 2 weeks	The number and the incidence of serious and non-serious adverse events observed in each treatment will be used to assess the safety and tolerability

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics Characteristics， t½ of GB001 recombinant peptide	Up to 240 minutes after last dose	Apparent terminal phase half-life
Pharmacokinetics Characteristics , Ctrough of GB001 recombinant peptide	Up to 240 minutes after last dose	Trough plasma concentration
Pharmacokinetics Characteristics , Cmax of GB001 recombinant peptide	Up to 240 minutes after last dose	Maximum plasma concentration
Pharmacokinetics Characteristics , Tmax of GB001 recombinant peptide	Up to 240 minutes after last dose	Time of maximum plasma concentration
Pharmacokinetics Characteristics , AUC of GB001 recombinant peptide	Up to 240 minutes after last dose	Area under the plasma concentration versus time curve
Pharmacokinetics Characteristics , Vd of GB001 recombinant peptide	Up to 240 minutes after last dose	Apparent distribution volume

Trial Locations

Locations (1)

The First Affiliated Hospital of Nanjing medical University; 🇨🇳 Nanjing, Jiangsu, China